Incyte (INCY) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
February 14, 2017 7:00 AM EST$238 million of 2016 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 30 percent growth over the same period last year and $853 million of 2016 full-year net product revenues from Jakafi, representing 42 percent growth over last year Multiple pivotal programs expected to commence this year, including the combination of epacadostat and pembrolizumab in four additional solid tumor indications Expanding early-stage R&D portfolio, including the FGFR4 inhibitor program as well as recent collaborations in the fields of bispecific antibodies and arginase inhibition... More
